OABI
OmniAb, Inc.
Overview
OmniAb licenses antibody discovery technology platforms to pharmaceutical, biotechnology, and academic partners to accelerate identification of therapeutic antibody candidates.
OmniAb, Inc is a Healthcare company operating in Biotechnology with a $336.4M market cap.
OABI beat consensus EPS by 0.4% in Q1 FY2026, reported May 7, 2026.
14 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-076 Q&A exchanges
- Q4 FY2025Earnings2026-03-0514 Q&A exchanges
- Q3 FY2025Earnings2025-11-0418 Q&A exchanges
- Q2 FY2025Earnings2025-08-0710 Q&A exchanges
- Q1 FY2025Earnings2025-05-0815 Q&A exchanges
- Q4 FY2024Earnings2025-03-1816 Q&A exchanges
- Q3 FY2024Earnings2024-11-1215 Q&A exchanges
- Q2 FY2024Earnings2024-08-1014 Q&A exchanges
- Q1 FY2024Earnings2024-05-099 Q&A exchanges
- Q4 FY2023Earnings2024-03-2022 Q&A exchanges
- Q3 FY2023Earnings2023-11-1424 Q&A exchanges
- Q2 FY2023Earnings2023-08-1211 Q&A exchanges
- Q1 FY2023Earnings2023-05-1220 Q&A exchanges
- Q4 FY2022Earnings2023-04-0221 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-07EPS$-0.06 vs $-0.10+38.0%Rev$14.4M vs ——EODHD
- Q4 FY20252026-03-04EPS$-0.11 vs $-0.09-25.7%Rev$8.4M vs ——EODHD
- Q3 FY20252025-11-03EPS$-0.14 vs $-0.13-7.7%Rev$2.2M vs ——EODHD
- Q2 FY20252025-08-05EPS$-0.15 vs $-0.13-15.4%Rev$3.9M vs ——EODHD
- Q1 FY20252025-05-06EPS$-0.17 vs $-0.17-2.0%Rev$4.2M vs ——EODHD
- Q4 FY20242025-03-17EPS$-0.12 vs $-0.10-24.1%Rev$10.8M vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.16 vs $-0.14-14.3%Rev$4.2M vs ——EODHD
- Q2 FY20242024-08-07EPS$-0.13 vs $-0.17+23.5%Rev$7.6M vs ——EODHD
- Q1 FY20242024-05-08EPS$-0.19 vs $-0.16-18.8%Rev$3.8M vs ——EODHD
- Q4 FY20232024-03-19EPS$-0.14 vs $-0.15+6.7%Rev$4.8M vs ——EODHD
- Q3 FY20232023-11-08EPS$-0.16 vs $-0.14-14.3%Rev$5.5M vs ——EODHD
- Q2 FY20232023-08-09EPS$-0.15 vs $-0.12-25.0%Rev$6.9M vs ——EODHD
- Q1 FY20232023-05-10EPS$-0.08 vs $-0.03-100.0%Rev$16.9M vs ——EODHD
- Q4 FY20222023-03-29EPS$0.07 vs $0.02+100.0%Rev$35.3M vs ——EODHD
- Q3 FY20222022-11-09EPS$-0.09 vs $0.00—Rev$6.9M vs ——EODHD
- Q2 FY20222022-08-11EPS$-0.06 vs ——Rev$7.2M vs ——EODHD
- Q1 FY20222022-05-19EPS$-0.16 vs ——Rev$9.6M vs ——EODHD
- Q4 FY20212022-03-27EPS$-0.01 vs ——Rev$15.3M vs ——EODHD
- Q3 FY20212021-11-09EPS$-0.01 vs ——Rev$6.3M vs ——EODHD
- Q2 FY20212021-09-22EPS$0.00 vs $0.00—Rev$5.6M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-07 | $-0.06 | $-0.10 | +38.0% | $14.4M | — | — | EODHD |
| Q4 FY2025 | 2026-03-04 | $-0.11 | $-0.09 | -25.7% | $8.4M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $-0.14 | $-0.13 | -7.7% | $2.2M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $-0.15 | $-0.13 | -15.4% | $3.9M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.17 | $-0.17 | -2.0% | $4.2M | — | — | EODHD |
| Q4 FY2024 | 2025-03-17 | $-0.12 | $-0.10 | -24.1% | $10.8M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.16 | $-0.14 | -14.3% | $4.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.13 | $-0.17 | +23.5% | $7.6M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.19 | $-0.16 | -18.8% | $3.8M | — | — | EODHD |
| Q4 FY2023 | 2024-03-19 | $-0.14 | $-0.15 | +6.7% | $4.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.16 | $-0.14 | -14.3% | $5.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.15 | $-0.12 | -25.0% | $6.9M | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.08 | $-0.03 | -100.0% | $16.9M | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $0.07 | $0.02 | +100.0% | $35.3M | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.09 | $0.00 | — | $6.9M | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.06 | — | — | $7.2M | — | — | EODHD |
| Q1 FY2022 | 2022-05-19 | $-0.16 | — | — | $9.6M | — | — | EODHD |
| Q4 FY2021 | 2022-03-27 | $-0.01 | — | — | $15.3M | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.01 | — | — | $6.3M | — | — | EODHD |
| Q2 FY2021 | 2021-09-22 | $0.00 | $0.00 | — | $5.6M | — | — | EODHD |
Source: EODHD. OABI reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks OABI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.12 | $1.50 | -25.5% | -1.4% | -2.6% |
| Q4 FY2026 | $1.18 | $1.51 | -22.1% | -8.0% | -10.9% |
| Q3 FY2026 | $1.33 | $1.62 | -17.9% | -3.3% | -5.8% |
| Q2 FY2026 | $1.22 | $1.42 | -14.0% | +1.2% | +1.0% |
| Q1 FY2025 | $1.43 | $1.63 | -12.5% | +1.3% | +2.6% |
| Q4 FY2025 | $1.20 | $1.52 | -21.3% | -7.6% | -8.6% |
| Q3 FY2025 | $1.15 | $1.53 | -24.9% | -6.3% | -3.7% |
| Q2 FY2025 | $1.26 | $1.52 | -17.0% | +1.1% | +2.7% |
| Q1 FY2024 | $1.43 | $1.61 | -10.9% | -1.0% | -3.2% |
| Q4 FY2024 | $1.38 | $1.73 | -20.1% | +1.0% | +2.6% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Matthew W FoehrCEO1 yr 4 mo14 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- Kurt A GustafsonCFO1 yr 4 mo14 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- Charles S BerkmanChief Legal Officer1 yr 2 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for OABI.
$ curl https://api.spokenalpha.com/v1/companies/OABIFAQ
Frequently asked about OABI
Where can I find OmniAb, Inc.'s (OABI) earnings call transcripts?
Spoken Alpha indexes OABI's earnings call transcripts at https://spokenalpha.com/companies/OABI. Each call links to attributed speakers and parsed analyst Q&A. OmniAb, Inc.'s own investor relations page is at https://investors.omniab.com/overview/default.aspx.
When was OmniAb, Inc.'s most recent earnings call?
OmniAb, Inc. (OABI) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is OABI in?
OmniAb, Inc. (OABI) operates in the Healthcare sector (Biotechnology industry).